financial statements 123 Hikma PHarmaceuticals Plc annual report 2011 17. deferred tax the following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting year.
the following is the analysis of the deferred tax balances after offset for financial reporting purposes: 2011 2010 $000 $000 deferred tax liabilities 23,147 12,404 deferred tax assets 36,072 23,288 12,925 10,884 no deferred tax asset has been recognised on temporary differences totalling usD 64,514, 000 2010: usD 56,690,000 due to the unpredictability of the related future profit streams.
Of these temporary differences, usD 41,925,000 relate to unrecognised deferred tax on unrealised intra-group profits and usD 5,945,000 in respect of deferred tax not recognised on uk share-based payments.
the remaining temporary differences of usD 16,644,000 relate to losses on which no deferred tax is recognised.
Of these losses usD 909,000 relate to losses which may be carried forward for one year before expiry and usD 822,000 relate to losses which may be carried forward for four years before expiry.
no deferred tax liability is recognised on temporary differences of usD 39,201,000 2010: usD 35,682,000 million relating to the unremitted earnings of overseas subsidiaries as the Group is able to control the timing of the reversal of these temporary differences and it is probable that they will not reverse in the foreseeable future.
